In this clinical study, the immunogenicity of the monovalent aluminium-adjuvanted whole virus vaccine (A/ H5N1) with a haemagglutinin content of 27µg HA per dose in adults aged 18-60 years (N=49) was also evaluated following a 0, 21 day schedule.